Multi-target inhibitors for proteins associated with Alzheimer: In silico discovery using fragment-based descriptors

Current Alzheimer Research

Volumn 10, Issue 2, 2013, Pages 117-124

  Speck Planche, Alejandro ^a   Kleandrova, Valeria V ^a,b   Luan, Feng ^a   Cordeiro, M Natália D S ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b MOSCOW STATE UNIVERSITY OF FOOD PRODUCTION   (Russian Federation)

Author keywords

Anti AD agents; Fragment; Linear discriminant analysis; Mt inhibitors; QSAR; Quantitative contributions

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMYLOID BETA PROTEIN; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; PRESENILIN 1;

ALZHEIMER DISEASE; ARTICLE; COMPUTER MODEL; HUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ALZHEIMER DISEASE; COMPUTER SIMULATION; DRUG DESIGN; HUMANS; MODELS, BIOLOGICAL; PROTEINS; SENSITIVITY AND SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84874970036     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011310020001     Document Type: Article

References (56)

1. Giordano M, Dominguez LJ, Vitrano T, Curatolo M, Ferlisi A, Di Prima A, et al. Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer's disease (AD). Archiv Gerontol Geriatr 51: 245-249 (2010).
2. Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, Boustani M, et al. The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health 23: 213-231 (2002).
3. Yang Y, Zhu L, Chen X, Zhang H. Binding research on flavones as ligands of beta-amyloid aggregates by fluorescence and their 3D-QSAR, docking studies. J Mol Graph Model 29: 538-545 (2010).
4. Sivaprakasam P, Xie A, Doerksen RJ. Probing the physicochemical and structural requirements for glycogen synthase kinase-3alpha inhibition: 2D-QSAR for 3-anilino-4-phenylmaleimides. Bioorg Med Chem 14: 8210-8218 (2006).
5. Garcia I, Fall Y, Gomez G, Gonzalez-Diaz H. First computational chemistry multi-target model for anti-Alzheimer, anti-parasitic, anti-fungi, and anti-bacterial activity of GSK-3 inhibitors in vitro, in vivo, and in different cellular lines. Mol Divers 15: 561-567 (2011).
6. Goodarzi M, Freitas MP, Jensen R. Feature selection and linear/nonlinear regression methods for the accurate prediction of glycogen synthase kinase-3beta inhibitory activities. J Chem Inf Model 49: 824-832 (2009).
7. Santana L, Gonzalez-Diaz H, Quezada E, Uriarte E, Yanez M, Vina D, et al. Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem 51: 6740-6751 (2008).
8. Ul-Haq Z, Mahmood U, Jehangir B. Ligand-based 3D-QSAR studies of physostigmine analogues as acetylcholinesterase inhibitors. Chem Biol Drug Des 74: 571-581 (2009).
9. Todeschini R, Consonni V. In: Handbook of Molecular Descriptors. (Ed: Manhnhold R, Kubinyi H and Timmerman H). Weinheim, New York, Chichester, Brisbane, Singapore, Toronto: WILEY-VCH Verlag GmbH (2000).
10. Todeschini R, Consonni V. In: Molecular Descriptors for Chemoinformatics. (Ed: Manhnhold R, Kubinyi H and Folkers G). Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA (2009).
11. Speck-Planche A, Kleandrova VV, Luan F, Cordeiro MNDS. Fragment-based QSAR model toward the selection of versatile anti-sarcoma leads. Eur J Med Chem 46: 5910-5916 (2011).
12. Speck-Planche A, Kleandrova VV, Rojas-Vargas JA. QSAR model toward the rational design of new agrochemical fungicides with a defined resistance risk using substructural descriptors. Mol Divers 15: 901-909 (2011).
13. Speck-Planche A, Scotti MT, García-López A, Emerenciano VP, Molina-Pérez E, Uriarte E. Design of novel antituberculosis compounds using graph-theoretical and substructural approaches. Mol Divers 13: 445-458 (2009).
14. Talete-srl. DRAGON for Windows (Software for Molecular Descriptor Calculations). v5.3. Milano, (2005).
15. Viswanadhan VN, Ghose AK, Revankar GR, Robins RK. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comput Sci 29: 163-172 (1989).
16. Kubinyi H. In: QSAR: Hansch analysis and related approaches. (Ed: Manhnhold R, Krogsgaard-Larsen P and Timmerman H). Weinheim, New York, Basel, Cambridge, Tokyo: VCH Publishers (1993).
17. Estrada E, Gonzalez H. What are the limits of applicability for graph theoretic descriptors in QSPR/QSAR? Modeling dipole moments of aromatic compounds with TOPS-MODE descriptors. J Chem Inf Comput Sci 43: 75-84 (2003).
18. Estrada E, Diaz GA, Delgado EJ. Predicting infinite dilution activity coefficients of organic compounds in water by quantum-connectivity descriptors. J Comput Aided Mol Des 20: 539-548 (2006).
19. Estrada E, Gutierrez Y. Modeling chromatographic parameters by a novel graph theoretical sub-structural approach. J Chromatogr A 858: 187-199 (1999).
20. Estrada E, Quincoces JA, Patlewicz G. Creating molecular diversity from antioxidants in Brazilian propolis. Combination of TOPS-MODE QSAR and virtual structure generation. Mol Divers 8: 21-33 (2004).
21. Estrada E, Peña A. In silico studies for the rational discovery of anticonvulsant compounds. Bioorg Med Chem 8: 2755-2770 (2000).
22. Estrada E, Pena A, Garcia-Domenech R. Designing sedative/hypnotic compounds from a novel substructural graph-theoretical approach. J Comput Aided Mol Des 12: 583-595 (1998).
23. Estrada E, Uriarte E. Quantitative structure-toxicity relationships using TOPS-MODE. 1. Nitrobenzene toxicity to Tetrahymena pyriformis. SAR QSAR Environ Res 12: 309-324 (2001).
24. Estrada E, Uriarte E, Gutierrez Y, Gonzalez H. Quantitative structure-toxicity relationships using TOPS-MODE. 3. Structural factors influencing the permeability of commercial solvents through living human skin. SAR QSAR Environ Res 14: 145-163 (2003).
25. Helguera AM, Gonzalez MP, Cordeiro MNDS, Perez MA. Quantitative structure carcinogenicity relationship for detecting structural alerts in nitroso-compounds. Toxicol Appl Pharmacol 221: 189-202 (2007).
26. Morales Helguera A, Perez Gonzalez M, Cordeiro MNDS, Cabrera Perez MA. Quantitative structure-carcinogenicity relationship for detecting structural alerts in nitroso compounds: species, rat; sex, female; route of administration, gavage. Chem Res Toxicol 21: 633-642 (2008).
27. Helguera AM, Perez-Machado G, Cordeiro MNDS, Combes RD. Quantitative structure-activity relationship modelling of the carcinogenic risk of nitroso compounds using regression analysis and the TOPS-MODE approach. SAR QSAR Environ Res 21: 277-304 (2010).
28. Estrada E. Spectral moments of the edge adjacency matrix in molecular graphs. 1. Definition and applications for the prediction of physical properties of alkanes. J Chem Inf Comput Sci 36: 844-849 (1996).
29. Estrada E. Spectral moments of the edge adjacency matrix in molecular graphs. 2. Molecules containing heteroatoms and QSAR applications. J Chem Inf Comput Sci 37: 320-328 (1997).
30. Estrada E. Spectral moments of the edge adjacency matrix in molecular graphs. 3. Molecules containing cycles. J Chem Inf Comput Sci 38: 23-27 (1998).
31. Estrada E, Uriarte E, Montero A, Teijeira M, Santana L, De Clercq E. A novel approach for the virtual screening and rational design of anticancer compounds. J Med Chem 43: 1975-1985 (2000).
32. Estrada E, Molina E, Perdomo-Lopez I. Can 3D structural parameters be predicted from 2D (topological) molecular descriptors? J Chem Inf Comput Sci 41: 1015-1021 (2001).
33. Gonzalez-Diaz H, Prado-Prado F, Garcia-Mera X, Alonso N, Abeijon P, Caamano O, et al. MIND-BEST: Web Server for Drugs and Target Discovery; Design, Synthesis, and Assay of MAO-B Inhibitors and Theoretical-Experimental Study of G3PDH Protein from Trichomonas gallinae. J Proteome Res 10: 1698-1718 (2011).
34. EBI-Team. ChEMBL Database. http://www.ebi.ac.uk/chembldb/ (2010).
35. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349: 704-706 (1991).
36. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423: 435-439 (2003).
37. Sereno L, Coma M, Rodriguez M, Sanchez-Ferrer P, Sanchez MB, Gich I, et al. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis 35: 359-367 (2009).
38. Weinreb O, Mandel S, Bar-Am O, Yogev-Falach M, Avramovich-Tirosh Y, Amit T, et al. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics 6: 163-174 (2009).
39. Lewis PA, Perez-Tur J, Golde TE, Hardy J. The presenilin 1 C92S mutation increases abeta 42 production. Biochemical and Biophysical Research Communications 277: 261-263 (2000).
40. O'Neill MJ, Heckelman PE, Koch CB, Roman KJ, Eds. The Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals. New Jersey: Whitehouse Station, NJ: Merck & Co., Inc (2006).
41. Estrada E, Gutiérrez Y. MODESLAB. v1.5. Santiago de Compostela, (2002-2004).
42. Van Waterbeemd H. In: Chemometrics methods in molecular design. (Ed: Manhnhold R, Krogsgaard-Larsen P, Timmerman H). Weinheim, New York, Basel, Cambridge, Tokyo: VCH Publishers (1995).
43. Concu R, Dea-Ayuela MA, Perez-Montoto LG, Bolas-Fernandez F, Prado-Prado FJ, Podda G, et al. Prediction of enzyme classes from 3D structure: a general model and examples of experimental-theoretic scoring of peptide mass fingerprints of Leishmania proteins. J Proteome Res 8: 4372-4382 (2009).
44. Speck-Planche A, Kleandrova VV, Luan F, Cordeiro MNDS. Multi-target drug discovery in anti-cancer therapy: Fragment-based approach toward the design of potent and versatile anti-prostate cancer agents. Bioorg Med Chem 19: 6239-6244 (2011).
45. StatSoft. STATISTICA. Data analysis software system. v6.0. Tulsa, (2001).
46. Hanczar B, Hua J, Sima C, Weinstein J, Bittner M, Dougherty ER. Small-sample precision of ROC-related estimates. Bioinformatics 26: 822-830 (2010).
47. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36 (1982).
48. Speck-Planche A, Cordeiro MNDS. Current Drug Design of Anti-HIV Agents Through the Inhibition of C-C Chemokine Receptor Type 5. Curr Comput Aided Drug Des 7: 238-248 (2011).
49. Speck-Planche A, Cordeiro MNDS. Application of Bioinformatics for the search of novel anti-viral therapies: Rational design of anti-herpes agents. Curr Bioinform 6: 81-93 (2011).
50. Prado-Prado FJ, Borges F, Uriarte E, Perez-Montoto LG, Gonzalez-Diaz H. Multi-target spectral moment: QSAR for antiviral drugs vs. different viral species. Anal Chim Acta 651: 159-164 (2009).
51. Prado-Prado FJ, Garcia-Mera X, Gonzalez-Diaz H. Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorg Med Chem 18: 2225-2231 (2010).
52. Prado-Prado FJ, Borges F, Perez-Montoto LG, Gonzalez-Diaz H. Multi-target spectral moment: QSAR for antifungal drugs vs. different fungi species. Eur J Med Chem 44: 4051-4056 (2009).
53. Prado-Prado FJ, Uriarte E, Borges F, Gonzalez-Diaz H. Multi-target spectral moments for QSAR and Complex Networks study of antibacterial drugs. Eur J Med Chem 44: 4516-4521 (2009).
54. Montero-Torres A, Vega MC, Marrero-Ponce Y, Rolón M, Gómez-Barrio A, Escario JA. A novel non-stochastic quadratic fingerprints-based approach for the 'in silico' discovery of new antitrypanosomal compounds. Bioorg Med Chem 13: 6264-6275 (2005).
55. Casañola-Martin GM, Marrero-Ponce Y, Khan MT, Khan SB, Torrens F, Perez-Jimenez F, et al. Bond-based 2D quadratic fingerprints in QSAR studies: virtual and in vitro tyrosinase inhibitory activity elucidation. Chem Biol Drug Des 76: 538-545 (2010).
56. Speck-Planche A, Kleandrova VV, Scotti MT. Fragment-based approach for the in silico discovery of multi-target insecticides. Chemometr Intell Lab Syst 111: 39-45 (2012).